RAPP Reports $476.8M Cash, $19B Net Income, +94% YoY, Phase 2a Seizure Data, Phase 3 2026 Initiation, 90% Median Seizure Reduction, 22-Day Half-Life, 2026 End-Of-Phase 2 Meeting, 2027 PGTCS Trial, 2029 Funding, 2026 4Q Bipolar Results, 2026 2Q Phase 3
Rapport Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $37.11
-12% in 7d after detection
Post-detection moves
1h
—
1d
-4.7%
3d
-6.7%
7d
-12%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS